Literature DB >> 31061703

Patients With Chronic Liver Disease/Cirrhosis Should Not Take Statin Medications.

Christopher Kasia1,2, Steven J Scaglione1,2,3.   

Abstract

Entities:  

Year:  2019        PMID： 31061703      PMCID： PMC6491028          DOI： 10.1002/cld.788

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  26 in total

1.  Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing.

Authors:  Einar Björnsson; Elin I Jacobsen; Evangelos Kalaitzakis
Journal:  J Hepatol       Date:  2011-09-01       Impact factor: 25.083

2.  Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians.

Authors:  Fadi S Rzouq; Michael L Volk; Hilana H Hatoum; Siva K Talluri; Rajasekhara R Mummadi; Gagan K Sood
Journal:  Am J Med Sci       Date:  2010-08       Impact factor: 2.378

3.  The characteristics and clinical outcome of drug-induced liver injury: a single-center experience.

Authors:  Ramazan Idilman; Mehmet Bektas; Kubilay Cinar; Murat Toruner; Ethem Turgay Cerit; Beyza Doganay; Esra Erden; Hakan Bozkaya; Kadir Bahar; Selim Karayalcin; Irfan Soykan; Murat Palabiyikoglu; Hulya Cetinkaya; Cihan Yurdaydin; Abdulkadir Dokmeci; Ali Ozden
Journal:  J Clin Gastroenterol       Date:  2010-07       Impact factor: 3.062

4.  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.

Authors:  Naga Chalasani; Robert J Fontana; Herbert L Bonkovsky; Paul B Watkins; Timothy Davern; Jose Serrano; Hongqiu Yang; James Rochon
Journal:  Gastroenterology       Date:  2008-09-17       Impact factor: 22.682

5.  Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.

Authors:  Juan G Abraldes; Agustin Albillos; Rafael Bañares; Juan Turnes; Rosario González; Juan Carlos García-Pagán; Jaime Bosch
Journal:  Gastroenterology       Date:  2009-01-24       Impact factor: 22.682

6.  Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment.

Authors:  Tatjana Stojakovic; Thierry Claudel; Csilla Putz-Bankuti; Günter Fauler; Hubert Scharnagl; Martin Wagner; Harald Sourij; Rudolf E Stauber; Karl Winkler; Winfried März; Thomas C Wascher; Michael Trauner
Journal:  Atherosclerosis       Date:  2009-09-06       Impact factor: 5.162

7.  Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.

Authors:  Naga Chalasani; Hisham Aljadhey; Joe Kesterson; Michael D Murray; Stephen D Hall
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

8.  Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients.

Authors:  Jill E Martin; Teresa M Cavanaugh; Leslie Trumbull; Maryetta Bass; Fredrick Weber; Jaime Aranda-Michel; Michael Hanaway; Steven Rudich
Journal:  Clin Transplant       Date:  2008 Jan-Feb       Impact factor: 2.863

9.  Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  James H Lewis; Mary Ellen Mortensen; Steven Zweig; Mary Jean Fusco; Jeffrey R Medoff; Rene Belder
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

Review 10.  Drug-induced liver injury associated with statins.

Authors:  Mark W Russo; Martin Scobey; Herbert L Bonkovsky
Journal:  Semin Liver Dis       Date:  2009-10-13       Impact factor: 6.115
View more
  3 in total

1.  Novel Coconut Vinegar Attenuates Hepatic and Vascular Oxidative Stress in Rats Fed a High-Cholesterol Diet.

Authors:  Wachirawadee Malakul; Porrnthanate Seenak; Noppadon Jumroon; Siwaret Arikit; Sarawut Kumphune; Nitirut Nernpermpisooth
Journal:  Front Nutr       Date:  2022-03-09

2.  Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis.

Authors:  Yue Gu; Xueqin Yang; Hang Liang; Deli Li
Journal:  BMC Gastroenterol       Date:  2019-12-30       Impact factor: 3.067

Review 3.  Efficacy and safety of anti-hepatic fibrosis drugs.

Authors:  Konstantinos Damiris; Zaid H Tafesh; Nikolaos Pyrsopoulos
Journal:  World J Gastroenterol       Date:  2020-11-07       Impact factor: 5.742
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.